Skip to main content
Premium Trial:

Request an Annual Quote

Franz Hillenkamp, Michael Karas, Paul Herrling, Anthony Martin, Mark Skolnick, Wendell Wierenga, Mary Callan, Karen Vacarro, Julia Palm


Franz Hillenkamp from the University of M nster and Michael Karas from the University of Frankfurt, both in Germany, will receive the ABRF Award for Outstanding Contributions in Biomolecular Technologies at this week’s Association of Biomolecular Research Facilities annual meeting in Denver, Colo., according to the program. Both researchers received the 1997 ASMS Award for Distinguished Contribution to Mass Spectrometry by the American Society for Mass Spectrometry.

Agilent Technologies of Palo Alto, Calif., has formed a life sciences strategy advisory board. The first members are: Paul Herrling, director of corporate research at Novartis International and professor of drug discovery sciences at a the University of Basel; Anthony Martin, president and CEO of Molecular Probes; Mark Skolnick, founder and CSO of Myriad Genetics; and Wendell Wierenga, CEO of Syrrx.

Mary Callan has become vice president of business development at Exton, Pa.-based Morphotek. She joins the company from Exelixis, where she was director of business development. Prior to that, she was head of business development at Large Scale Biology.

Karen Vacarro has been appointed vice president of research and development of Matritech, based in Newton, Mass. Previously, she worked at companies that include Baxter International, Biotechnica Diagnostics, and Polaroid-Behring Diagnostic Systems.

Julia Palm, senior vice president for biomedical products and services, will retire from Charles River Laboratories of Wilmington, Mass., at the end of the year.


The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.